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Purpose	Integrative medicine interventions are needed for awake craniotomies, as many patients experience
anxiety. Lavender aromatherapy significantly reduces anxiety or pain in a variety of surgical procedures.
This feasibility study used lavender aromatherapy during awake craniotomies to determine the number
of patients who would consent and complete the study, the technicality of lavender aromatherapy use,
and acceptance by operating room (OR) staff.
Methods	We approached 40 consecutive patients (≥18 years old). Exclusion criteria were pulmonary issues or
sensitivity to lavender. Outcome measures in consented patients were enrollment and completion rates,
anxiety and pain as measured by the Visual Analog Scale for Anxiety (VAS-A) and Visual Analog Scale
for Pain (VAS-P), and satisfaction with pain control using the Patient Opinion of Pain Management
(POPM) survey.
Results 	Of the 40 patients approached, 4 declined participation or had their surgery cancelled. Of the
remaining 36, 4 required increased sedation during surgery and 1 was unable to detect lavender.
Thus, 31 patients (77.5%) completed the study. VAS-A and VAS-P scores trended lower after
lavender inhalation, but the difference did not reach statistical significance. There was a slight
increase in VAS-P score at the OR1 time point. Expectancy for reduction in both anxiety and pain
were not significantly different. Improvement in anxiety also was not different, while improvement in
pain trended lower (P=0.025). POPM results indicated the majority of patients were either “satisfied”
or “very satisfied” with pain management.
Conclusions	This study demonstrated 77.5% completion and the ability to integrate lavender aromatherapy into the
OR. Thus, we plan to conduct a randomized clinical trial to assess efficacy of lavender aromatherapy.
(J Patient Cent Res Rev. 2020;7:19-30.)
Keywords	
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deficits, as the patient is continuously assessed by both
physical examination and neurocognitive testing,1 a
reduction in operating time,2 and minimal postoperative
recovery and decreased length of hospital stay.3
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Aurora Integrative Medicine, Outpatient Health Center,
1020 N. 12th Street, 4th Floor, Milwaukee, WI 53233
(nancy.conway@aurora.org)

Although many patients tend to tolerate awake cranial
surgery well, recent studies have found that roughly
30% of patients experience moderate to severe pain
and anxiety,4 50% report moderate fear, and 11% report
severe fear.5 Therefore, alternative methods to mitigate
pain and anxiety are needed. Interventions that would
alleviate pain and anxiety during an awake craniotomy

wake craniotomy during brain surgery
permits monitoring of speech, motor, and
sensory function. This procedural approach
is increasingly utilized for its several advantages
over a traditional general anesthetic technique. These
advantages include minimization of new neurological
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without interfering with the neurocognitive exam are
limited. For example, a 1998 glioma study utilizing
hypnosis was found to have a favorable psychological
impact.6 However, hypnosis also has been shown to
inhibit left frontal lobe function and therefore influence
results of neurocognitive exams.7

pain as well as improve satisfaction with pain control
in patients undergoing awake cranial surgery. It was
our intention that results from this feasibility study
could be used to inform a subsequent randomized trial
to assess efficacy of lavender aromatherapy.

There is a growing body of literature related to the
use of lavender aromatherapy as an anxiolytic agent.
A study of 150 patients randomized into standard
of care, standard of care plus an unscented “sham”
aromatherapy, or standard of care plus lavender
aromatherapy found a significant decrease in anxiety
when transferred to the operating room, per the Visual
Analog Scale for Anxiety (VAS-A), in the lavender
aromatherapy group.8 Similarly, 93 women awaiting
breast surgery were randomized to receive lavender
aromatherapy or unscented oil. Anxiety, as measured
by the State-Trait Anxiety Inventory, was significantly
reduced in the lavender group.9

Study Design
This was a pilot single-arm clinical trial preparatory
to a randomized trial.16,17 The study was approved
by the Aurora Health Care (Aurora) institutional
review board, and the U.S. Food and Drug
Administration allowed the study to proceed
without an Investigational New Drug requirement.
This study is also listed on clinicaltrials.gov as
“Feasibility of Aromatherapy in an Awake Craniotomy
Environment”
(https://clinicaltrials.gov/ct2/show
/NCT03328143?term=aromatherapy&cond=awake+
craniotomy&rank=1).

There is also evidence to suggest that lavender
aromatherapy has an analgesic effect. Several studies
of patients with divergent procedures, including breast
biopsies, gastric banding, tonsillectomies, cesarean
sections, and coronary artery bypass grafts, all tested
whether lavender aromatherapy reduced pain intensity,
using the Visual Analog Scale for Pain (VAS-P), and
changed narcotic requirements.10-14 In the patients
receiving gastric banding or tonsillectomy, treatment
with lavender aromatherapy reduced use of narcotics
without a change in pain intensity,11,12 while in those
receiving cesarean section or coronary bypass, there
was a significant reduction in pain intensity with use of
lavender aromatherapy.13,14 In addition, a meta-analysis
of 12 studies reporting the use of aromatherapy to
manage pain determined that lavender aromatherapy
reduced pain on VAS-P.15
Based on these findings, we hypothesized that the
use of lavender aromatherapy during awake cranial
surgery could enhance patient comfort and therefore
merited clinical evaluation. To our knowledge,
lavender aromatherapy has not been utilized in an
awake craniotomy setting. Thus, this preparatory
trial was designed to assess the feasibility of lavender
aromatherapy intervention intraoperatively to evaluate
the effects of lavender aromatherapy on anxiety and
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METHODS

Primary objective was feasibility with several
endpoints: 1) Determine the percentage of patients
who would consent to participate; 2) Determine the
percentage of patients who would then complete the
study following consent to participate; 3) Determine
the technical aspects of administering lavender
aromatherapy in the operating theater; 4) Determine
the acceptance of lavender aromatherapy by multiple
anesthesiologists, neurosurgeons, neuropsychologists,
neuropsychometrists, and nursing staff. Secondary
objectives were to determine the impact of lavender
aromatherapy on pain and anxiety and to determine
patient satisfaction with pain control during awake
cranial surgery.
Outcome measures were enrollment and completion
rates, anxiety as measured by VAS-A (Figure 1A),18,19
pain intensity as measured by VAS-P (Figure 1B),20
and satisfaction with pain control as measured by the
Patient Opinion of Pain Management (POPM) survey.21
These three instruments are further detailed within the
“Subjective Assessment Tools” subsection.
Recruitment of Potential Research Subjects
Consecutive eligible patients were asked during
their preoperative evaluation if they would like to
participate in this clinical trial. This conversation took
place either in the outpatient clinic or the inpatient
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Figure 1. Visual analogue scales for anxiety and pain. Patients were asked to score their anxiety (A) and pain (B)
before, during, and after surgery.
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setting. Participating patients received Aurora-created
educational material regarding aromatherapy and
lavender. Planned enrollment was 40 patients.
Any adult patient (ie, ≥18 years of age) undergoing
awake cranial neurosurgery was eligible for inclusion.
At Aurora, awake cranial surgery is primarily used
for adult patients with benign or malignant extraaxial and intra-axial brain tumors. Exclusion criteria
were allergy or sensitivity to lavender (Lavandula
angustifolia); aversion to the lavender scent,
which included unpleasant associated memory in
patients who received a test dose of lavender scent
administered through a nasal inhaler; history of
asthma or chronic obstructive pulmonary disease;

history of contact dermatitis following exposure to
cosmetic fragrances; and pregnancy.
Study Procedures
The lavender aromatherapy trial protocol was
developed in conjunction with Aurora’s integrative
medicine department and certified clinical
aromatherapy practitioners (CCAP). Institutional
policy on aromatherapy (Aurora Policy 2032, dated
July 2012) provided additional guidance.
After informed consent was obtained, subjects were
given a brief expectancy questionnaire (Figure 2) to
delineate their preoperative expectations of outcomes
from their participation in the trial. The same
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questionnaires were administered after surgery, upon
the patient’s arrival to the neurosurgical intensive care
unit (Neuro-ICU).

participation was detrimental to the patient. Lavender
aromatherapy was administered for up to 5 minutes
using the nasal inhaler at designated time points
(preoperative, induction) and every 30 minutes
during the surgery (Figure 4). OR1 was the time at
which surgery was initiated, every 30-minute interval
thereafter received a consecutive number (OR2–OR5).
Although OR personnel administered the aromatherapy
most of the time, some patients were able to and chose
to self-administer. Additional lavender aromatherapy
treatments were provided at any time on request.
During non-use periods, the nasal inhaler was capped
and sealed.

Participating patients received standard-of-care
intraoperative analgesic and anxiolytic management
plus lavender aromatherapy. Lavender scent was
administered via nasal inhaler (Figure 3). The lavender
essential oil (Elizabeth Van Buren, Inc., Santa Cruz,
CA), base oil (Elizabeth Van Buren, Inc.), and nasal
inhaler (Bulk Apothecary, Aurora, OH) were provided
by the integrative medicine department to ensure
standardization across all patients. The nasal inhaler
was prepared with 15 gtts (drops) of lavender essential
oil and 4 gtts (drops) of the base oil (grapeseed oil).
If the subject was unable to verbally request the
A CCAP from integrative medicine provided training
research team member to hold the nasal inhaler under
on the delivery of lavender aromatherapy to all
their nose, the subject’s participation in the study
study team members. This person consulted on the
was terminated. Additionally, subjects were free to
participation of the first 3 subjects and was present in
discontinue administration of aromatherapy at any time
the operating room (OR) to oversee administration of
during their participation in the study. The timing and
Figure 4. reason
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Figure 4. Use of Visual Analog Scale for Anxiety
Figure 3. Components of the lavender inhaler (Bulk

Apothecary, Aurora, OH). A: Outer sealed sheath. B:
Inner inhaler. This is removed from the outer sheath to
provide focal inhalation of scent. C: Cotton wick to which
the lavender and base oils are applied. It is inserted
into (B) and sealed with end cap (D). E: The lavender
essential oil (Elizabeth Van Buren, Inc., Santa Cruz, CA).
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(VAS-A), Visual Analog Scale for Pain (VAS-P),
and Patient Opinion of Pain Management (POPM)
assessment tools at various study time points. Patients
were given lavender aromatherapy before the operation,
in the induction room, in the OR at the start of surgery
(OR1), and every 30 minutes thereafter (OR2–OR5).
The POPM was administered to patients in the
neurosurgical intensive care unit (Neuro-ICU).
www.aurora.org/jpcrr

23

Subjective Assessment Tools
The expectancy questionnaire consisted of 4 questions
(2 regarding anxiety and 2 regarding pain) asked and
answered before surgery and asked and answered after
surgery (Figure 2). For each outcome, the first question
asked the patient to evaluate how well they expected
their anxiety or pain to be reduced with lavender
aromatherapy. The second question asked the patient
to evaluate to what degree they expected their anxiety
or pain to be improved with lavender aromatherapy
(Figure 2, Preprocedure). Patients were then asked to
evaluate how well their anxiety or pain was actually
reduced or improved following surgery (Figure 2,
Postprocedure).
VAS-A and VAS-P scores were obtained on the
traditional 11-point scale, which ranges from 0 to 10
(Figure 1). Participating patients were asked to rate
their pain and anxiety before surgery (preop), during
induction (induction), at the start of surgery (OR1),
and at 30-minute intervals (OR2–OR5) (Figure 4).
The POPM tool employs a 5-point Likert scale for the
query “How satisfied are you with your pain treatment
overall?” This question was asked of subjects upon
arrival to the Neuro-ICU. Response choices were “Very
Dissatisfied,” “Dissatisfied,” “Uncertain,” “Satisfied,”
and “Very Satisfied.”
Statistical Plan
This feasibility study consisted of 40 participants.
Enrollment rate and trial completion rate were
calculated. Demographic characteristics were noted
using appropriate descriptive statistics for all categorical
and continuous variables. A total of 31 patients
completed the study and were included for analyses. As
both VAS-A and VAS-P were assessed multiple times
for the same patients, mean scores of these measures
were compared using the repeated measures analysis of
variance (ANOVA), including multivariate analysis of
variance (MANOVA) tests in the general linear model.
Expectancy questionnaire responses were analyzed
using a 2-sided, paired t-test. Mean POPM scores
were compared using an independent t-test. Predefined
subgroups included gender, primary vs metastatic
tumor, and age by decade. An alpha of 0.05 was used
for all statistical tests, and all analyses were done using
SAS® 9.4 (SAS Institute Inc., Cary, NC).
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Adverse Event Monitoring
This trial used the U.S. Department of Health and
Human Services’ Common Terminology Criteria for
Adverse Events, Version 4.0 (published May 28, 2009;
revised June 14, 2010) for toxicity and adverse event
reporting. Allergic, pulmonary, and gastrointestinal
adverse events were recorded.

RESULTS

From April 4, 2018, to January 2, 2019, 40 patients
were asked to enroll in this study; 3 declined (7.5%).
Patient characteristics are summarized in Table 1. All
surgeries took place at Aurora St. Luke’s Medical
Center (Milwaukee, WI). Two anesthesiologists,

Table 1. Study Population Characteristics
Characteristic

n*

Gender
Male
Female

19
21

Mean age

60 years

Pathology
Atypical meningioma
High-grade glioma
Low-grade glioma
Meningioma
Metastasis
Other
Sarcoma

1
12
3
3
7
4
1

Position
Half lateral
Lateral decubitus, left up
Lateral decubitus, right up
Supine
Supine, bump under shoulder

1
4
2
14
10

Self-description
A very anxious person
A not very anxious person
A high pain tolerance
A low pain tolerance

10
21
20
11

*Note: The 40 patients asked to participate in the study
make up gender and age categories; the 31 patients who
completed the study comprise the total for pathology,
position, and self-description categories.
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3
neurosurgeons,
2
neuropsychologists,
2
neuropsychometrists, and 1 circulating registered
nurse attended the patients in the OR.
Of the 40 patients approached, 36 consented to
participate in the trial. Four participants were unable to
complete the intraoperative portion of the trial due to
increased sedation needs, and 1 participant was unable
to smell the lavender during the surgery, although
that person had not met the exclusion criteria prior to
surgery. The inability to smell the lavender was felt to be
related to competing smells within the OR as opposed to
an inhaler failure, as OR personnel were able to detect
the lavender scent. In total, 31 patients (77.5% of the 40
approached, 86.1% of the 36 who consented) completed
all elements of the trial (Figure 5).
On an observational level, providing lavender
aromatherapy to patients appeared to be seamlessly
integrated into the neurocognitive exam and the
aromatherapy protocol was vocally embraced by many
members of the OR teams. When patients were asked
if they preferred to receive lavender aromatherapy
as needed or on a scheduled basis, 77% of patients
preferred to receive inhalations on an as-needed basis
compared with 23% who preferred the scheduled
inhalations.
Impact on Anxiety
Mean scores for VAS-A before lavender aromatherapy
were slightly higher than they were after aromatherapy
at each of the inhalation times: preop, induction, OR1–
OR5 (Figure 6A). Time points beyond OR5 had fewer
than 10 data points and therefore are not presented.
The trend toward reduced anxiety after lavender
aromatherapy did not reach statistical significance.
There was little difference between patients’ expected
and experienced anxiety relief (Figure 7, blue bars).
Impact on Pain and Pain Management
Mean scores for VAS-P were the same or slightly
higher before lavender aromatherapy compared to
after inhalation (Figure 6B). Again, this did not reach
statistical significance. A small increase in VAS-P
was noted after lavender aromatherapy at the OR1
time point. The reason for this is unclear. There was
little difference when patients were asked to rate
their expected reduction in pain compared to actual

Original Research

Figure 5. Consolidated Standards of Reporting Trials
(CONSORT) diagram.

pain reduction (Figure 7A, red bars), but there was a
significant drop in the amount of pain improvement
(Figure 7B, red bars) compared to the expected
improvement (P=0.025).
When POPM data were assessed, the majority of
patients were either “Satisfied” or “Very satisfied” with
their pain management (Figure 8).
Adverse Events
No immediate adverse events were noted. There were
no toxicity reactions and no pulmonary events. One
patient described unpleasant recall of the surgical
procedure when exposed to lavender scent after
surgery. There were no requests to discontinue lavender
aromatherapy.

DISCUSSION

The neurosurgical OR is a complex environment.
Moreover, there is a high level of coordination and
collaboration needed between OR team members:
neurosurgical, anesthesiology, neuropsychology,
nursing, and technical support. For awake patients,
there are additional challenges including the need
for constant monitoring of comfort, anxiety, and

www.aurora.org/jpcrr
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A.

B.

Figure 6. VAS-A (A) and VAS-P (B) scores, before and after lavender aromatherapy, at each implementation time

point. The OR1 time point correlated with the start of surgery, with OR2–OR5 indicating 30-minute intervals between
aromatherapy application. VAS-A, Visual Analog Scale for Anxiety; VAS-P, Visual Analog Scale for Pain.
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Figure 7. Expectancy questionnaire responses for anxiety and pain, obtained before and immediately after

surgery. A: Question: How successful do you think aromatherapy will be/was in reducing anxiety (blue bars) or
pain (red bars)? B: Question 2: By the end of this study, how much do you think your anxiety (blue bars) or pain
(red bars) will/did improve? *P=0.025.
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Figure 8. Patient Opinion of Pain Management survey results. Upon arrival in the neurosurgical intensive care unit,
patients were asked the question: “How satisfied are you with your pain treatment overall?” Response choices were
“Very Dissatisfied,” “Dissatisfied,” “Uncertain,” “Satisfied,” and “Very Satisfied.”

the neurocognitive exam.22 And while most surgical
patients experience a loss of control in the perioperative
period, this is magnified for awake patients, as they
are continuously aware of their restricted freedom of
movement during the operation.23 In fact, we found a
high percentage of patients wished to self-administer
lavender aromatherapy, which we did not necessarily
anticipate. This is an interesting finding that will be
taken into consideration when designing the tools
and statistical analyses for a clinical trial, as we need
to know whether this impacts efficacy of lavender
aromatherapy in any way.
Therefore, adoption of a new intraoperative intervention
during awake craniotomy should be weighed against
the imperatives of improved patient comfort and sense
of control, enhanced collaboration among the surgical
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team, and a willing engagement by OR personnel. In
this study, lavender aromatherapy performed favorably
against these measures. Enrollment and satisfaction
rates were high.
Previously published literature demonstrates that
lavender aromatherapy has both anxiolytic and
analgesic properties.8-15 Indeed, in this study there
was a trend toward an anxiolytic benefit with use of
lavender aromatherapy. This trend was not statistically
significant, but efficacy was not the intent of this study.
Additionally, awake cranial surgery in this pilot study
was comfortable; baseline VAS-P and VAS-A scores
were quite low, providing little room for improvement
with lavender aromatherapy. There was a reduction
in the improvement of pain reported by patients after
surgery compared with their expected improvement
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prior to surgery, and it is unclear at this time what
might have caused this change. However, this study
did find that patients were willing to use aromatherapy,
the technique was quite feasible, and the intervention
was adopted without complaint.
Integrative medicine interventions are underutilized,
and this study highlights their applicability within a
complex environment such as awake cranial surgery
in the neurosurgical OR. Aside from selection of
music, there are limited options for patients to feel in
control in the OR. The ability to exert control through
lavender aromatherapy proved important, as evidenced
by the overwhelming preference for aromatherapy to
be delivered on request rather than on a predetermined
schedule. The factor of control may indeed prove to be
significant in future studies.
Limitations of this study include the fact that there is a
large placebo effect for conditions such as anxiety and
pain24,25 as well as the inability to find an equivalent
placebo. Furthermore, potential benefit to the patient
may reside largely in their increased sense of control in
self-administering the lavender aromatherapy.
Despite the limitations, these encouraging results
support a larger trial that is powered to assess efficacy
in the setting of awake craniotomy.

CONCLUSIONS

This study highlights the possible applications of
intraoperative lavender aromatherapy during awake
cranial neurosurgical procedures. Based on the
percentage of patients who consented and eventually
completed the study as well as the technical ability
to offer lavender aromatherapy within the OR, we
conclude that lavender aromatherapy was feasible
and will continue to be offered to patients on an
as-needed basis during awake cranial surgery. In
addition, the results from this feasibility study will be
used to inform a randomized trial to assess efficacy of
lavender aromatherapy. We feel that using integrative
medicine approaches (especially those that may
increase patient control of their environment) in the
context of awake cranial surgery opens novel avenues
of inquiry that may benefit our patients and therefore
merit continued exploration.
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Patient-Friendly Recap
• Performing brain surgery while a patient
remains awake carries many advantages over
use of general anesthesia, but this approach
can increase patients’ anxiety about and
during the procedure.
• The authors tested a protocol that allowed
patients to receive lavender aromatherapy
through an inhaler during their awake
craniotomy.
• While anxiety and pain scores did not
significantly improve from lavender,
implementation of the aromatherapy proved
feasible and was associated with positive
patient satisfaction.
• Further study of lavender aromatherapy
in patients having awake brain surgery is
warranted.
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